Korea Investment Partners — 2021 Investments
1 investments dated 2021 · listed companies and verified rows first · show all
Rgenta develops orally available small molecule therapies that target RNA to address diseases previously considered undruggable, with programs in oncology (targeting proteins such as MYB in solid tumors and hematologic cancers) and central nervous system repeat expansion disorders like Huntington's disease.
AI & Machine LearningBiotechDeep TechHealthtechCambridge, US
Travis Wager(Co-founder, President and CSO)Hualin Simon Xi(Executive Officer, Director)Zhiping Weng(Co-founder)Simon Xi(Co-founder and CEO)Jackie Walling(CMO)Debasish Roychowdhury(Director)
Co-investorsDelos CapitalVivo CapitalAMR Action FundLilly Asia Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.